SecBot SecBot

OKYO

OKYO Pharma Ltd
Nasdaq· Biological Products, (No Diagnostic Substances)· CIK 0001849296 Biotech & Drug Discovery
$1.49 +0.05 (+3.47%)
Oct 27 4:00 PM ET · prev $1.44
Market cap
$73.5M
Micro cap
Median target
$7.00
+370% · range $5.00–13.00
1 year
−41.6%
from $2.55 · Oct 28
30 days
+8.8%
from $1.37
52-week range
$1.29–3.11
−52% from high · low Sep 30
Avg volume 20D
46.8K
Oct 21 spike 241.0K
Short interest
76.7K
≈0.1% of shares · +121.3%
Days to cover
1.8
at average volume
Insider net
+$136.0K
6 buyers · 0 sellers · 12 mo
Filing reports
23
analyzed by SecBot
SecBot read BULLISH 5 reports · 90 days
Balance 0 bearish · 3 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 2/5
Strongest BULLISH OKYO Pharma announced first patients enrolled in the Phase 3 NEPTUNE pivotal trial of urcosimod for…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    6 insiders bought $136.0K at an average $1.44. No open-market sales.

  • Short sellersBUILDING

    Short interest +121.3% to 76.7K shares. 1.8 days to cover, ≈0.1% of shares.

  • TrendUPTREND

    3% above its 50-day average.

Who's buying

13F
Top holderSharesValue
Woodline Partners LP3,652,768$5.5M
BALYASNY ASSET MANAGEMENT L.P.580,596$870.9K
UBS Group AG55,009$82.5K
Quantinno Capital Management LP33,255$49.9K
Cerity Partners LLC12,812$19.2K
GEODE CAPITAL MANAGEMENT, LLC12,090$18.1K
RENAISSANCE TECHNOLOGIES LLC11,200$16.8K
JANE STREET GROUP, LLC10,302$15.5K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jul 2026
12-month targets · 3 analysts

Price is below the lowest target. Median implies +370%.Targets as of Oct 28, 2026.

Recent actions
DateFirmActionRating
Jul 13, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 6, 2026
FDA
OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain
LONDON and NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing…
Sep 8, 2026
Press release
OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference
LONDON and NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing…
Jul 27, 2026
Press release
OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026
LONDON and NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing…
Jul 23, 2026
Activist
OKYO Pharma Announces Purchase of Shares by Director
LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing…
Jul 23, 2026
Press release
OKYO Pharma Announces Purchase of Shares by Chief Executive Officer
LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing…

Insider ledger

Form 4
$136.0K
bought · 6 insiders
$0
sold · 0 insiders
+3.4%
vs their $1.44 cost
DateInsiderTypeValue
Jul 27, 2026
Patil Rajkumar V.
Chief Scientific Officer
BUY$5.0K
Jul 27, 2026
Patil Rajkumar V.
Chief Scientific Officer
AWARD$5.0K
Jul 22, 2026
Dempsey Robert John
CHIEF EXECUTIVE OFFICER
BUY$23.1K
Jul 22, 2026
Dempsey Robert John
CHIEF EXECUTIVE OFFICER
AWARD$23.1K
Jul 21, 2026
Mantelli Flavio
CHIEF MEDICAL OFFICER
BUY$28.0K
Jul 21, 2026
CERRONE GABRIELE M
Director
BUY$32.6K
Jul 21, 2026
BRANCACCIO JOHN P
Director
BUY$7.4K
Jul 21, 2026
JACOB GARY S
CHIEF DEVELOPMENT OFFICER
BUY$4.9K

Earnings setup

Estimates
−$0.03
EPS estimate, this quarter
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.03-$0.03–-$0.03+0.0%$0.00
Next Q-$0.04-$0.04–-$0.04+0.0%$0.00
Current FY-$0.12-$0.12–-$0.12+0.0%$0.00
Next FY-$0.66-$0.66–-$0.66+0.0%$11.0M

Short side

FINRA· Oct 15, 2026
76,652
shares short
+121.3%
vs prior settlement
1.8
days to cover
≈0.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 6, 2026 SEC
OKYO Pharma announced first patients enrolled in the Phase 3 NEPTUNE pivotal trial of urcosimod for neuropathic…
6-K — Impact 6/10
Oct 6, 2026 Press
OKYO Pharma announced first patients enrolled in the Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain…
Impact 6/10
Oct 6, 2026 FDA
OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain
LONDON and NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinic
Sep 29, 2026 SEC
OKYO Pharma announced its participation and presentation at upcoming ophthalmic conferences (Eyecelerator, American…
6-K — Impact 3/10
Sep 8, 2026 SEC
OKYO Pharma filed a 6-K announcing participation at the Cantor Global Healthcare Conference (Sept 9-11, 2026) with a…
6-K — Impact 3/10
Jul 27, 2026 Insider
Patil Rajkumar V. bought 3,363 shares
Chief Scientific Officer @ $1.49 ($5.0K)
Jul 27, 2026 Insider
Patil Rajkumar V. was granted 3,363 shares
Chief Scientific Officer @ $1.49 ($5.0K)
Jul 23, 2026 Press
OKYO Pharma issued a press release announcing that Non-Executive Director John Brancaccio purchased 5,000 ordinary…
Impact 2/10

SecBot reports

23 filings · 6 press releases · 7 bullish · 0 bearish · 16 neutral
All OKYO filing & press-release reports (29)